规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
500mg |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
体外活性:阿折地平是一种新开发的长效钙通道阻滞剂,具有独特的药理特性,如心脏减慢作用和对血管组织的高亲和力,使其与其他钙通道阻滞剂区别开来。因此,阿折地平成为新一代钙通道阻滞剂,可用于治疗患有或不患有潜在缺血性心脏病的高血压患者。由于这种新型钙拮抗剂具有高度脂溶性,因此从血液中清除后,它会保留在血管壁中,并持续引起降血压作用。
|
||
---|---|---|---|
体内研究 (In Vivo) |
不适用
|
||
动物实验 |
|
||
参考文献 |
Hypertens Res.2003 Mar;26(3):201-8;Int J Pharm.2008 Mar 3;351(1-2):55-60.
|
分子式 |
C33H34N4O6
|
---|---|
分子量 |
582.65
|
CAS号 |
123524-52-7
|
相关CAS号 |
Azelnidipine-d7
|
SMILES |
O=C(C1=C(N)NC(C)=C(C(OC(C)C)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OC3CN(C(C4=CC=CC=C4)C5=CC=CC=C5)C3
|
InChi Key |
ZKFQEACEUNWPMT-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C33H34N4O6/c1-20(2)42-32(38)27-21(3)35-31(34)29(28(27)24-15-10-16-25(17-24)37(40)41)33(39)43-26-18-36(19-26)30(22-11-6-4-7-12-22)23-13-8-5-9-14-23/h4-17,20,26,28,30,35H,18-19,34H2,1-3H3
|
化学名 |
3-(1-benzhydrylazetidin-3-yl) 5-isopropyl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
|
别名 |
UR-12592; UR-12592; UR-12592; CS 905; CS-905; CS905; CCRIS 8650; CCRIS8650; CCRIS-8650; Azelnidipine; trade name CalBlock.
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
---|
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 1.7163 mL | 8.5815 mL | 17.1630 mL | |
5 mM | 0.3433 mL | 1.7163 mL | 3.4326 mL | |
10 mM | 0.1716 mL | 0.8581 mL | 1.7163 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT00294567 | Completed | Drug: Calcium channel blockers (amlodipine, azelnidipine) |
Hypertension Coronary Atherosclerosis |
Juntendo University | December 2005 | Phase 4 |
NCT01028534 | Completed | Drug: Olmesartan and Azelnidipine | Obstructive Sleep Apnea Hypertension |
Kyoto University, Graduate School of Medicine |
July 2010 | Not Applicable |
NCT00607035 | Completed | Drug: Olmesartan medoxomil +Azelnidipine |
Hypertension | Jichi Medical University | May 2006 | Phase 4 |
NCT00454662 | Completed | Drug: olmesartan medoxomil / amlodipine or azelnidipine |
Hypertension Cardiovascular Disease |
COLM Study Research Organization | April 2007 | Phase 4 |
Contractile properties of cardiomyocytes isolated from control, diabetic rats and diabetic rats treated with AZL (5 mg kg-1 day-1). td> |
Intracellular Ca2+ transient properties of ventricular myocytes isolated from control, diabetic rats and diabetic rats treated with AZL (5 mg kg-1 day-1). td> |
Generation of O 2 ·- in ventricular myocytes isolated from control, diabetic rats and diabetic rats treated with AZL (5 mg kg-1 day-1). td> |